The company’s expanded label for Avtozma (tocilizumab-anoh) now includes the treatment of cytokine release syndrome, aligning ...

For the first target addressed in the partnership, the two companies reported the successful delivery of AI-designed, ...

The agency’s new program is designed to increase regulatory predictability and streamline review of domestic manufacturing ...

The investment will expand the company’s manufacturing and packaging capabilities at its Maple Grove, Minn. site, which Bora ...

The company presented new data from its Alzheimer’s disease research efforts across its diagnostics and pharmaceutical ...

A new nuclear magnetic resonance method reveals real-time, coordinated changes in nanoemulsion drugs, improving noninvasive ...

Jerry Keybl, senior vice-president, Biopharma Products and Strategy, Avantor, discusses innovations in biomanufacturing and ...

Findings from a Phase III study highlight the demonstrated action of donanemab-azbt (brand name Kisunla) in slowing the ...

Jonathan D. Grinstein, PhD, Manfred Scholz, PhD, and Erik Wiklund, PhD, go behind the headlines to address a shifting policy landscape and what it means for the future of chronic disease, diagnostics, ...

Orforglipron showed clinically meaningful results at 72 weeks, after three doses, in a pool of more than 3000 adults.

Radiopharmaceuticals are moving from their standard use of treating superficial tumors into radio drug conjugates that target ...

The program has been transitioned to a permanent pathway that is designed to support innovative tools like artificial ...